Protect your patients’ path toward remission

The National Cancer Comprehensive Network® (NCCN) recommendation for G-CSF use during chemotherapy

UDENYCA® delivers the reliable outcomes you expect, but with 35% cost savings per dose vs Neulasta®.*2

Discover the value of UDENYCA®

UDENYCA® was confirmed to be highly similar to Neulasta®, with no clinically meaningful differences.3,4

View proven biosimilarity

* Based on wholesale acquisition cost (WAC). WAC does not necessarily reflect actual prices paid by consumers, pharmacies, or third-party payers. UDENYCA® WAC of $4175 per prefilled syringe vs Neulasta® WAC of $6417 per prefilled syringe.

References: 1. Kuderer, M. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia. J Clin Oncol. 2007;25(21):1-10. 2. Data on file. Coherus BioSciences, Inc.; 2023. 3. UDENYCA® (pegfilgrastim-cbqv) Prescribing Information. Redwood City, CA: Coherus BioSciences, Inc.; 2023. 4. Neulasta® (pegfilgrastim) Prescribing Information. Thousand Oaks, CA: Amgen Inc.; 2021.